A report entitled “State of the global biomanufacturing and bioprocessing industry 2017” was published in September 2017 by William Reed’s BioPharma-Reporter. The report is based on a state-of-the-industry survey, answered by more than 350 people, covering topics such as current bioprocessing challenges, investment and capacity, cell lines and disposable technologies.
Given that Vironova focusses on supporting gene therapy applications within biologicals and biomanufacturing, it is heartening to read that, in answer to the question:
“Which biological products will disrupt the biomanufacturing industry over the next few years?”
60 % of the respondents answered “Cell & Gene therapy.”
And given that Vironova offers, above-all, automation that helps in monitoring processes, it was also good to see that in answer to:
“Where do you see the most need for investment and innovation in the biomanufacturing industry?”
and
“Which technology advances will disrupt the biomanufacturing industry over the next few years?”
the commonest answer was “automation and monitoring (and process controls)”.
You can download the full report here.
